Search Within

Michael John Mauro

Formats
  1. Meeting Abstract (187)
  2. Journal Article (67)
  3. Review (7)
  4. Correspondence (4)
  5. Research Letter (3)
  6. Book Section (2)
  7. Editorial (2)
  8. Guidelines (2)
Groups
  1. Adult Leukemia (274)
  2. Center for Hematologic Malignancies (274)
  3. Department of Medicine (274)
  4. Hematologic Malignancies, Division of (274)
  5. Biostatistics Service (10)
  6. Epidemiology and Biostatistics (10)

More Groups

People
  1. Raajit Rampal (12)
  2. Ellin Berman (8)
  3. Eytan Stein (8)
  4. Martin Tallman (7)
  5. Amber King (6)
  6. Andriy Derkach (6)

More People

Years
  1. 2025 (5)
  2. 2024 (17)
  3. 2023 (26)
  4. 2022 (33)
  5. 2021 (21)
  6. 2020 (26)

More Years

Publications
  1. Blood (97)
  2. Clinical Lymphoma, Myeloma and Leukemia (44)
  3. Journal of Clinical Oncology (22)
  4. Haematologica (21)
  5. Leukemia (12)
  6. American Journal of Hematology (8)

More Publications

Publishers
  1. American Society of Hematology (101)
  2. Elsevier Inc. (47)
  3. American Society of Clinical Oncology (22)
  4. Ferrata Storti Foundation (21)
  5. Nature Publishing Group (12)
  6. John Wiley & Sons, Inc. (8)

More Publishers

Results (274)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms
    Research Letter

    King, A. C.; Weis, T. M.; Derkach, A.; Ball, S.; Pandey, M.; Mauro, M. J.; Goldberg, A. D.; Stahl, M.; Famulare, C.; Tallman, M. S.; more...
    American Journal of Hematology (2022)

    Fulltext@MSK | Save
  • COVID-19 in patients with chronic myeloid leukemia: Poor outcomes for patients with comorbidities, older age, advanced phase disease, and those from low-income countries: An update of the candid study
    Meeting Abstract

    Pagnano, K. B.; Kok, C. H.; Mauro, M. J.; Cortes, J. E.; Evans, N.; Jiang, Q.; Milojkovic, D.; Moiraghi, B.; Nicolini, F. E.; Ongondi, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Efficacy and safety results from ascembl, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: Update after 48 weeks
    Meeting Abstract

    Mauro, M. J.; Minami, Y.; Rea, D.; Hochhaus, A.; Lomaia, E.; Voloshin, S.; Turkina, A. G.; Kim, D. W.; Apperley, J. F.; Cortes, J. E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Dose modification dynamics of ponatinib in patients with chronic- phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
    Meeting Abstract

    Jabbour, E.; Deininger, M.; Abruzzese, E.; Apperley, J. F.; Cortes, J. E.; Chuah, C.; DeAngelo, D.; DiPersio, J. F.; Hochhaus, A.; Lipton, J. H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Post hoc analysis of responses to ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) by baseline BCR-ABL1 level and baseline mutation status in the OPTIC trial
    Meeting Abstract

    Deininger, M. W.; Apperley, J. F.; Arthur, C. K.; Chuah, C.; Hochhaus, A.; De Lavallade, H.; Lipton, J. H.; Lomaia, E.; McCloskey, J. K.; Maness, L. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • An update of safety and efficacy results from phase 1 dose-escalation and expansion study of vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI), in patients with chronic myeloid leukemia (CML) and philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) failing prior TKI therapies
    Meeting Abstract

    Cortes, J. E.; Saikia, T.; Kim, D. W.; Alvarado, Y.; Nicolini, F. E.; Rathnam, K.; Khattry, N.; Apperley, J. F.; Deininger, M. W.; de Lavallade, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Trial in progress: Asciminib in monotherapy 4 CML (AIM4CML), a phase IIIb study of asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without or with T315I mutations
    Meeting Abstract

    Andorsky, D.; Tomassetti, S.; Deutsch, Y. E.; Broun, E. R.; Issa, G. C.; Levy, M. Y.; Deininger, M. W.; Maegawa, R.; Shrestha, A.; Mauro, M. J.
    Blood (2021)

    Fulltext@MSK | Save
  • Lifelong TKI therapy: How to manage cardiovascular and other risks
    Review

    Mauro, M. J.
    Hematology-American Society of Hematology Education Program (2021)

    Fulltext@MSK | Save
  • A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
    Journal Article

    Réa, D.; Mauro, M. J.; Boquimpani, C.; Minami, Y.; Lomaia, E.; Voloshin, S.; Turkina, A.; Kim, D. W.; Apperley, J. F.; Abdo, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines
    Research Letter

    Kozak, K. E.; Ouyang, L.; Derkach, A.; Sherman, A.; McCall, S. J.; Famulare, C.; Chervin, J.; Daley, R. J.; Morjaria, S.; Mauro, M. J.; more...
    Leukemia (2021)

    Fulltext@MSK | Save